{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:43:04Z","timestamp":1778107384453,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clon.2025.103909","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T06:40:04Z","timestamp":1753339204000},"page":"103909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The Royal College of Radiologists\u2019 Re-Audit of UK Prostate Brachytherapy Delivery"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-9583","authenticated-orcid":false,"given":"A.","family":"Challapalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6811-3736","authenticated-orcid":false,"given":"P.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-5269","authenticated-orcid":false,"given":"K.","family":"Drinkwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9283-1327","authenticated-orcid":false,"given":"A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2025.103909_bib1","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ng131. [cited 2025 03 March]."},{"issue":"5.5","key":"10.1016\/j.clon.2025.103909_bib2","first-page":"583","article-title":"NCCN Guidelines Updates: Management of Prostate Cancer","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clon.2025.103909_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.urology.2019.09.040","article-title":"Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer","volume":"136","author":"Goy","year":"2020","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brachy.2005.12.002","article-title":"Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","volume":"5","author":"Martens","year":"2006","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline. Part III: Principles of Radiation and Future Directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.clon.2025.103909_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103909_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2025.103909_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103909_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.radonc.2021.12.047","article-title":"GEC-ESTRO ACROP prostate brachytherapy guidelines","volume":"167","author":"Henry","year":"2022","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103909_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clon.2015.02.005","article-title":"The Royal College of Radiologists' audit of prostate brachytherapy in the year 2012","volume":"27","author":"Stewart","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2025.103909_bib11","series-title":"Quality assurance practice guidelines for transperineal LDR permanent seed brachytherapy of prostate cancer","year":"2012"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103909_bib13","article-title":"Brachytherapy dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer (adults) (210502P) [URN 1831]","year":"2021","journal-title":"Clin Commissioning Policy"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmir.2023.05.043","article-title":"A two-center experience: The impact of COVID-19 on two brachytherapy programs in Ontario - virtual care, service suspension and radiation therapy workflow","volume":"54","author":"Chan","year":"2023","journal-title":"J Med Imag Radiat Sci"},{"issue":"6","key":"10.1016\/j.clon.2025.103909_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35795","article-title":"Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States","volume":"131","author":"Sebastian","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5114\/jcb.2018.76839","article-title":"UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016","volume":"10","author":"Corey","year":"2018","journal-title":"J Contemp Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2021.07.004","article-title":"PSA: Declining utilization of prostate brachytherapy","volume":"21","author":"Andring","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.clon.2025.103909_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2020.07.036","article-title":"Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada","volume":"152","author":"Corkum","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brachy.2021.06.148","article-title":"Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016","volume":"21","author":"Mukherjee","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.clon.2025.103909_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2020.09.025","article-title":"Challenges influencing the utilization of prostate brachytherapy in the United States","volume":"154","author":"Odei","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2025.103909_bib21","first-page":"19","article-title":"Real-world utilisation of brachytherapy boost and patient-reported functional outcomes in men who had external beam radiation therapy for prostate cancer in Australia","volume":"37","author":"Ong","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2016.07.013","article-title":"Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices","volume":"96","author":"Orio","year":"2016","journal-title":"Implications Future Resid Train Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2025.103909_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.brachy.2017.03.007","article-title":"Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer","volume":"16","author":"Jackson","year":"2017","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.clon.2025.103909_bib24","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.06.020","article-title":"Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer","volume":"72","author":"Johnson","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/pcan.2017.15","article-title":"Trends in the use of radiation therapy for stage IIA prostate cancer from 2004 to 2013: a retrospective analysis using the National Cancer Database","volume":"20","author":"Malouff","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"14","key":"10.1016\/j.clon.2025.103909_bib26","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/cncr.28697","article-title":"The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base","volume":"120","author":"Martin","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clon.2025.103909_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.brachy.2016.05.001","article-title":"The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness","volume":"15","author":"Orio","year":"2016","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.clon.2025.103909_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brachy.2013.08.005","article-title":"Declining use of brachytherapy for the treatment of prostate cancer","volume":"13","author":"Mahmood","year":"2014","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103909_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clon.2013.01.001","article-title":"Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"10.1016\/j.clon.2025.103909_bib31","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/j.ijrobp.2011.11.040","article-title":"Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate","volume":"82","author":"Lawton","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijrobp.2018.10.023","article-title":"Brachytherapy Training Survey of Radiation Oncology Residents","volume":"103","author":"Marcrom","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2025.103909_bib34","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3389\/fonc.2019.01378","article-title":"A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate","volume":"9","author":"Fischer-Valuck","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103909_bib35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.brachy.2020.07.003","article-title":"#ThisIsBrachytherapy: Increasing awareness of brachytherapy","volume":"20","author":"Kahn","year":"2021","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.clon.2025.103909_bib36","article-title":"Recognition of education, training and experience in advanced clinical practice through a national multiprofessional scheme: A narrative review from a radiographer participant","volume":"56","author":"Cain","year":"2025","journal-title":"J Med Imag Radiat Sci"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:17:32Z","timestamp":1758082652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"alternative-id":["S0936655525001645"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103909","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Royal College of Radiologists\u2019 Re-Audit of UK Prostate Brachytherapy Delivery","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103909"}}